Scancell Receives FDA Clearance for Phase 3 Trial of iSCIB1+ Immunobody in Advanced Melanoma
Key Insights
Scancell Holdings (search) received FDA clearance for a registrational phase 3 trial of its iSCIB1+ (search) Immunobody in advanced melanoma (search) patients.
The company completed its SCOPE phase 2 study evaluating SCIB1 and iSCIB1+ (search) in combination with nivolumab plus ipilimumab in previously untreated unresectable stage IIIB/IV melanoma (search).
Progression-free survival has been agreed as the surrogate endpoint for the phase 3 trial.
Oxford-based pharmaceutical company Scancell Holdings (search) has received clearance from the US Food & Drug Administration for its investigational new drug application to proceed with a registrational phase 3 trial of its iSCIB1+ (search) Immunobody in advanced melanoma (search). The FDA has agreed to progression-free survival as the surrogate endpoint for the pivotal study.
Phase 2 Study Completion and Key Findings
Scancell has completed its SCOPE phase 2 open-label, multi-centre study evaluating ImmunoBody immunotherapies SCIB1 and iSCIB1+ (search) in combination with nivolumab plus ipilimumab. The study enrolled previously untreated patients with unresectable stage IIIB/IV melanoma (search), representing a challenging patient population with significant unmet medical needs.
The company's analysis of the phase 2 data has yielded promising results, with Scancell reporting potentially best-in-class efficacy and durability for its immunotherapy approach. This data analysis has also enabled the identification of a selection marker that will be used to enrich the phase 3 trial for patients most likely to respond to treatment.
Strategic Advantages for Phase 3 Development
The identification of a patient selection marker represents a significant strategic advantage for Scancell's phase 3 development program. By enriching the trial population for likely responders, the company aims to maximize the probability of demonstrating clinical benefit while potentially reducing the required sample size and development timeline.
The combination approach utilizing Scancell's proprietary ImmunoBody technology alongside established checkpoint inhibitors nivolumab and ipilimumab builds upon the proven efficacy of immune checkpoint blockade in melanoma while potentially offering enhanced therapeutic benefits through the company's novel immunotherapy platform.
Regulatory Pathway and Clinical Significance
The FDA's acceptance of progression-free survival as a surrogate endpoint provides a clear regulatory pathway for potential accelerated approval, should the phase 3 trial demonstrate significant clinical benefit. This endpoint selection aligns with established regulatory precedents in advanced melanoma (search) and could facilitate faster patient access to the therapy if successful.
The advancement to phase 3 represents a critical milestone for Scancell's ImmunoBody platform, moving the company closer to potential commercialization of its novel immunotherapy approach in one of the most challenging oncology indications.